A Look At Dyne Therapeutics (DYN) Valuation After Orphan Drug Win And Upcoming Neuromuscular Data

Simply Wall St.

Feb 23

Dyne Therapeutics (DYN) is back in focus after highlighting five upcoming presentations at the 2026 Muscular Dystrophy Association conference and securing Orphan Drug designation in Japan for its ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2613079382"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2613079382\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2613079382?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-02-23 15:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613079382","market":"sg","top_or_hot":-1,"title":"A Look At Dyne Therapeutics (DYN) Valuation After Orphan Drug Win And Upcoming Neuromuscular Data","media":"Simply Wall St.","content":"<div>\n<p>Dyne Therapeutics (DYN) is back in focus after highlighting five upcoming presentations at the 2026 Muscular Dystrophy Association conference and securing Orphan Drug designation in Japan for its ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dyn/dyne-therapeutics/news/a-look-at-dyne-therapeutics-dyn-valuation-after-orphan-drug\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Dyne Therapeutics (DYN) Valuation After Orphan Drug Win And Upcoming Neuromuscular Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Dyne Therapeutics (DYN) Valuation After Orphan Drug Win And Upcoming Neuromuscular Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-23 15:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dyn/dyne-therapeutics/news/a-look-at-dyne-therapeutics-dyn-valuation-after-orphan-drug><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dyne Therapeutics (DYN) is back in focus after highlighting five upcoming presentations at the 2026 Muscular Dystrophy Association conference and securing Orphan Drug designation in Japan for its ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dyn/dyne-therapeutics/news/a-look-at-dyne-therapeutics-dyn-valuation-after-orphan-drug\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴资本持仓","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dyn/dyne-therapeutics/news/a-look-at-dyne-therapeutics-dyn-valuation-after-orphan-drug","article_id":"2613079382","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dyn/dyne-therapeutics/news/a-look-at-dyne-therapeutics-dyn-valuation-after-orphan-drug","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2613079382","pubTimestamp":1771831064,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Dyne Therapeutics (DYN) is back in focus after highlighting five upcoming presentations at the 2026 Muscular Dystrophy Association conference and securing Orphan Drug designation in Japan for its myotonic dystrophy type 1 therapy.\nSee our latest analysis for Dyne Therapeutics.\nDespite the recent regulatory and conference catalysts, Dyne Therapeutics’ short term momentum has cooled, with a 30 day share price return decline of 17.33% and a 90 day decline of 31.33%, even as the 1 year total...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4505":"高瓴资本持仓","BK4139":"生物科技","DYN":"戴纳基","BK4585":"ETF&股票定投概念","BK4588":"碎股","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc"},"translate_title":"孤儿药获奖和即将发布的神经肌肉数据后达因治疗(DYN)估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DYN":1.5,"DCF":1},"content_text":"Dyne Therapeutics (DYN) is back in focus after highlighting five upcoming presentations at the 2026 Muscular Dystrophy Association conference and securing Orphan Drug designation in Japan for its myotonic dystrophy type 1 therapy. See our latest analysis for Dyne Therapeutics. Despite the recent regulatory and conference catalysts, Dyne Therapeutics’ short term momentum has cooled, with a 30 day share price return decline of 17.33% and a 90 day decline of 31.33%, even as the 1 year total shareholder return of 6.21% and 3 year total shareholder return of 28.28% point to a stronger longer term picture. If progress in neuromuscular therapies has your attention, this can be a good moment to broaden your watchlist with 27 healthcare AI stocks surfaced by the Simply Wall St screener. With the share price pulling back over the past few months while long term returns remain positive, the key question is now whether Dyne Therapeutics is trading below its potential or if the market is already pricing in future growth. AdvertisementDCF Valuation: What the SWS Model Implies for Dyne Therapeutics Dyne Therapeutics last closed at $14.88, while our DCF model estimates a future cash flow value of $66.99, which points to a steep valuation gap. The SWS DCF model builds this estimate by projecting the company’s future cash flows and discounting them back to today using a required rate of return. That gives a single present value figure that can be compared directly to the current share price. For Dyne Therapeutics, a clinical stage neuromuscular disease company with minimal reported revenue and a net loss of $423.801m, a cash flow based approach focuses on what its pipeline might generate if its programs succeed. In early stage biotech, that kind of framework is common because traditional earnings based metrics are not very informative while the company is still loss making. Look into how the SWS DCF model arrives at its fair value. Result: DCF Fair value of $66.99 (UNDERVALUED) However, you still need to weigh execution and funding risk, given Dyne’s clinical stage focus, minimal revenue, and reported net loss of $423.801m. Find out about the key risks to this Dyne Therapeutics narrative. Another Angle: What P/B Says About Dyne The SWS model also looks at Dyne through its P/B ratio of 3.5x. That sits well below the 10.7x average of peers, yet above the broader US Biotechs average of 2.6x. This creates a mixed picture of how cautiously or optimistically the market is pricing its assets. See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:DYN P/B Ratio as at Feb 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Dyne Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 54 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps If this mix of opportunity and risk feels finely balanced, it is a good time to look through the details yourself and decide where you stand, including weighing up 1 key reward and 3 important warning signs to see how the trade off looks to you. Looking for more investment ideas? If Dyne is on your radar, do not stop there. Use this moment of focus to line up a few more opportunities that genuinely fit your style.  Target resilient income by scanning for companies in our 15 dividend fortresses that combine higher yields with a focus on consistency. Hunt for potential bargains using the 54 high quality undervalued stocks, where strong fundamentals meet prices that may not fully reflect them. Spot lesser known opportunities early with the screener containing 23 high quality undiscovered gems, highlighting quality names that many investors may be overlooking.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}